
Note: The budget period dates in slides 20 & 21 are changed from the original webinar version. This slide deck has the correct dates.

Q&A Webinar

June 23, 2022 @ 3:00 PM EDT

Please submit your questions in the "Q&A" box (scientific inquiries will not be discussed) NIH DIRECTOR'S NEW INNOVATOR AWARD





National Institutes of Health Office of Strategic Coordination - The Common Fund

Q&A Webinar

- Submit questions in the "Q&A" box
- Scientific or situationally specific questions will not be discussed (email us)
- For additional questions, contact us at <u>NewInnovatorAwards@mail.nih.gov</u>
- Webinar recording & slides will be posted on website at <u>commonfund.nih.gov/newinnovator</u>
- For more application guidance, see our <u>Application</u> <u>& Award Guide</u> on website (includes example applications)







Panelists

Ravi Basavappa, Ph.D.

Program Leader Office of the Director

Trish Labosky, Ph.D.

Program Leader Office of the Director

Becky Miller, Ph.D.

Program Officer Office of the Director

Eugene Carstea, Ph.D.

Branch Chief Center for Scientific Review

Tony Kirilusha, Ph.D.

Program Director National Institute of Arthritis and Musculoskeletal and Skin Diseases

Ellie Murcia, M.Ed.

Program Specialist Office of the Director

Common Fund Programs

- 4D Nucleome (4DN)
- Acute to Chronic Pain Signatures (A2CPS)
- Bridge to Artificial Intelligence (Bridge2AI)
- Cellular Senescence Network (SenNet)
- Enhancing the Diversity of the NIH-Funded Workforce (DPC/BUILD)
- Extracellular RNA Communication (exRNA)
- Faculty Institutional Recruitment for Sustainable Transformation (FIRST)
- Gabriella Miller Kids First
- Global Health
- Glycoscience
- Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa)
- HCS Research Collaboratory
- High-Risk, High-Reward Research Program
 - Pioneer Award
 - New Innovator Award
 - Transformative Research Award
 - Early Independence Award
- Human BioMolecular Atlas Program (HuBMAP)

- Illuminating the Druggable Genome (IDG)
- Knockout Mouse Phenotyping (KOMP)
- Library of Integrated Network-Based Cellular Signatures (LINCS)
- Metabolomics
- Molecular Transducers of Physical Activity Consortium (MoTrPAC)
- *Nutrition for Precision Health*, powered by *All of Us* Research Program
- Somatic Cell Genome Editing (SCGE)
- Somatic Mosaicism Across Human Tissues (SMaHT)
- Stimulating Peripheral Activity to Relieve Conditions (SPARC)
- Transformative High Resolution Cryo-Electron Microscopy (CryoEM)
- Transformative Research to Address Health Disparities and Advance Health Equity
- Undiagnosed Diseases Network (UDN)



Common Fund Programs

- 4D Nucleome (4DN)
- Acute to Chronic Pain Signatures (A2CPS)
- Bridge to Artificial Intelligence (Bridge2AI)
- Cellular Senescence Network (SenNet)
- Enhancing the Diversity of the NIH-Funded Workforce (DPC/BUILD)
- Extracellular RNA Communication (exRNA)
- Faculty Institutional Recruitment for Sustainable Transformation (FIRST)
- Gabriella Miller Kids First
- Global Health
- Glycoscience
- Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa)
- HCS Research Collaboratory
- High-Risk, High-Reward Research Program
 - Pioneer Award
 - New Innovator Award
 - Transformative Research Award
 - Early Independence Award
- Human BioMolecular Atlas Program (HuBMAP)

- Illuminating the Druggable Genome (IDG)
- Knockout Mouse Phenotyping (KOMP)
- Library of Integrated Network-Based Cellular Signatures (LINCS)
- Metabolomics
- Molecular Transducers of Physical Activity Consortium (MoTrPAC)
- *Nutrition for Precision Health*, powered by *All of Us* Research Program
- Somatic Cell Genome Editing (SCGE)
- Somatic Mosaicism Across Human Tissues (SMaHT)
- Stimulating Peripheral Activity to Relieve Conditions (SPARC)
- Transformative High Resolution Cryo-Electron Microscopy (CryoEM)
- Transformative Research to Address Health Disparities and Advance Health Equity
- Undiagnosed Diseases Network (UDN)

CF programs may be useful for your research: FOAs, access to high-end instruments, databases, reagents, protocols,



Common Fund Programs

- 4D Nucleome (4DN)
- Acute to Chronic Pain Signatures (A2CPS)
- Bridge to Artificial Intelligence (Bridge2AI)
- Cellular Senescence Network (SenNet)
- Enhancing the Diversity of the NIH-Funded Workforce (DPC/BUILD)
- Extracellular RNA Communication (exRNA)
- Faculty Institutional Recruitment for Sustainable Transformation (FIRST)
- Gabriella Miller Kids First
- Global Health
- Glycoscience
- Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa)
- HCS Research Collaboratory
- High-Risk, High-Reward Research Program
 - Pioneer Award
 - New Innovator Award
 - Transformative Research Award
 - Early Independence Award
- Human BioMolecular Atlas Program (HuBMAP)

- Illuminating the Druggable Genome (IDG)
- Knockout Mouse Phenotyping (KOMP)
- Library of Integrated Network-Based Cellular Signatures (LINCS)
- Metabolomics
- Molecular Transducers of Physical Activity Consortium (MoTrPAC)
- *Nutrition for Precision Health*, powered by *All of Us* Research Program
- Somatic Cell Genome Editing (SCGE)
- Somatic Mosaicism Across Human Tissues (SMaHT)
- Stimulating Peripheral Activity to Relieve Conditions (SPARC)
- Transformative High Resolution Cryo-Electron Microscopy (CryoEM)
- Transformative Research to Address Health Disparities and Advance Health Equity
- Undiagnosed Diseases Network (UDN)





Supporting outstanding scientists at all career stages proposing high-risk, high-impact research





Annual funding opportunities





High-risk, high-impact ideas





No preliminary data or detailed experimental plan required





Any topic relevant to NIH mission welcome

Behavioral, social, biomedical, applied, and formal sciences, and basic, translational, or clinical research





Encourage applications from investigators with diverse backgrounds and from the full spectrum of eligible institutions



HRHR Working Group

Chair

James Anderson (OD)

Program Leader

Ravi Basavappa (OD)

Members

Kristin Abraham (NIDDK) Hugh Auchincloss (NIAID) Abraham Bautista (NIAAA) Sangeeta Bhargava (NEI) Gene Carstea (CSR) Robert Carter (NIAMS) Jennifer Collins (NIEHS) Christine Colvis (NCATS) Emmeline Edwards (NCCIH) Zeynep Erim (NIBIB) Rene Etcheberrigaray (NIA)

Nancy Freeman (NIDCD) Dana Greene-Schloesser (OD) Jane Hettinger (NINDS) Gabriel Hidalgo (NIDCR) Ray Jacobson (CSR) Flora Katz (FIC) Anthony Kirilusha (NIAMS) Susan Koester (NIMH) Trish Labosky (OD) James Li (CSR) Roger Little (NIDA) James Mack (CSR) Becky Miller (OD) Brett Miller (NICHD) Daniel Miller (NINDS) David Miller (NCI) Michael Morse (OD)

Ellie Murcia (OD) Imoh Okon (CSR) Richard Palmer (NLM) Steven Pittenger (NCATS) Srikanth Ranganathan (CSR) Diana Rutberg (NIDCR) Suzanne Ryan (CSR) John Satterlee (NIDA) Carol Shreffler (NIEHS) Lillian Shum (NIDCR) Darren Sledjeski (NIGMS) Heidi Sofia (NHGRI) Barbara Sorkin (OD) Nathaniel Stinson (NIMHD) Stephanie Webb (NHLBI) Elizabeth Wilder (OD)





Supports unusually creative early career investigators proposing innovative, highimpact research

- Started in 2007
- Early Stage Investigator (no substantial NIH grant and within 10 years of doctoral degree or clinical training)
- Commit 25% research effort
- Awards of \$1.5 million disbursed in two segments (change from previous years)
- Uses DP2 activity code



DP2 Application

Follow instructions in SF424 application guide unless specific guidance is provided in the FOA

Specific Aims Page	Do not use
Research Strategy Essay	10 pages (primary component of the application; see later slide for more information)
Biosketch	Only PI's biosketch allowed
Bibliography & References Cited	Do not use; include essential in references in Essay and within 10- page limit
Budget	Minor budget details required
Equipment	Do not use
Letters of support	Do not use
Resource Sharing Plan	Do not use; will be requested as Just-in-Time information
Other components/forms	Use when appropriate, such as Authentication of Key Biol./Chem. Resources; Vertebrate Animals; Human Subjects; Biohazards



Research Strategy Essay

In 10 pages, use the following headings or subsections:

- **Project science areas** 1 digit code and abbreviation for primary and secondary areas
- Project Description Describe scientific importance of topic; overall approach to be taken; preliminary data not required, but accepted; state that to comply with the FOA, a detailed experimental plan and extensive are not being provided; however, provide sufficient evidence that proposal has been deeply considered and will be pursued in a robust and rigorous manner
- Innovativeness Provide argument of why proposal is exceptionally innovative
- **Investigator qualifications** Support your claim of innovativeness in prior research
- Suitability for the New Innovator Award program Describe why proposal is "HRHR"
- Statement of research effort commitment State will commit at least 25% research effort toward project
- Bibliography/citations Include critical citations; may be in an abbreviated form as long as identifier is unique



Research Strategy Essay -Points to Consider

- Given review process used, be sure that what you write can be easily appreciated by people well
 outside the field for exceptional innovation and potential for unusually broad impact
- May be helpful to begin with a description of the landscape of the field and current state-of-theart or boundaries; provide proper context for proposal and why it is so innovative and potentially impactful
- Ease the reader into the jargon of the field
- Though no data or detailed experimental plan are required, convince the reviewer that you have thought deeply about the project – identify risky aspects, how they will be mitigated, alternate approaches
- Also, convince the reviewer that the research will be performed in a robust and rigorous manner

 validate new approaches, provide estimates of numbers of human or animal subjects (if used)
 and why, include that sex will be considered as a biological variable (if appropriate)



Budget Periods

To comply with recent changes in HHS and NIH policy regarding multi-year funded (MYF) awards, New Innovator Award funds will no longer be disbursed in the first year for the entire \sim 5-year project period.

Instead, awards will be made in two MYF segments: one for the first three years and the second for the final two years.

This means that no-cost extensions beyond the initial five-year project period will be allowed.



Annual budgets <u>are</u> required in the application, but to help maintain budget flexibility, only minimum information is requested.

The budgets have the following two important constraints:

- For the first segment (9/1/2023 8/31/2026), the total direct cost must not exceed \$900,000.
- For the second segment (9/1/2026 8/31/2028), the total direct cost must not exceed \$600,000.




Per the FOA instructions:

1. Select the appropriate Budget Type. (Project),


2. Provide the Budget Period Start Date and End Date - September 1 of one year and August 31 of the next calendar year, respectively. First budget period would be 9/1/2023 – 8/31/2024.

3. Section A: Senior/Key Persons provide an entry for the PD/PI, including the appropriate level of effort, and enter \$0 for Requested Salary and \$0 for Fringe Benefits. Entering \$0 does not imply that the PD/PI will not receive any salary or fringe benefit support from the grant.





4. In Section C: Enter budget request for equipment. Provide justification using the Budget Justification.





5. In Section F: Other Direct Costs add a line item titled 'Requested Direct Costs' and provide the total direct cost request for that budget period. If equipment is requested in Section C, do not add the equipment budget in Section F.

"Requested Direct Costs" covers everything except equipment costs for that budget period (including salaries, fringe benefits, supplies, travel, and other permitted costs)

6. Ensure that the two budget
constraints described above are met:
≤ \$900,000 direct costs for years 1 – 3

 \leq \$600,000 direct costs for years 4 – 5

	Materials and Supplies						Funds Requested (\$)
	Publication Costs						
3.							
	ADP/Computer Services	_					
- 4 . 5.	Subawards/Consortium/						
	Equipment or Facility Re						
	Alterations and Renoval						
<i>'</i> .	Alterations and Renoval	uons					
▶8.							
9.							
10.							L
				т	otal Othe	r Direct Costs	
<u>G. I</u>	Direct Costs						Funds Requested (\$)
				Total Dire	ct Cost	s (A thru F)	
H. I	ndirect Costs						
					ndirect (Cost Base (\$)	Evende Deserved (f)
	Indirect Cost Type		Indirect Co	ost Rate (%) I	nairect		Funds Requested (\$)
	Indirect Cost Type			ost Rate (%)	nairect	JUST 2036 (\$)	Funds Requested (\$)
	Indirect Cost Type			ost Rate (%)	nairect		Funas Requestea (\$)
	Indirect Cost Type					lirect Costs	runas Requestea (\$)
	nizant Federal Agency						
(Age							Funds Requested (\$)
(Age POC	gnizant Federal Agency ency Name, POC Name, and Phone Number)	ct Coste					
(Age POC	gnizant Federal Agency ancy Name, POC Name, and			T	otal Inc	lirect Costs	Funds Requested (\$)
(Age POC	inizant Federal Agency ncy Name, POC Name, and Phone Number) otal Direct and Indire		rect and India	T	otal Inc	lirect Costs	Funds Requested (\$)
(Age POC	inizant Federal Agency ncy Name, POC Name, and Phone Number) otal Direct and Indire			T	otal Inc	lirect Costs	
(Age POC <u>I. T</u>	unizant Federal Agency mcy Name, POC Name, and Phone Number) otal Direct and Indire Fee			T	otal Inc	lirect Costs	Funds Requested (\$)
(Age POC <u>I. T</u>	inizant Federal Agency ncy Name, POC Name, and Phone Number) otal Direct and Indire			Tect Instituti	otal Inc	bsts (G + H)	Funds Requested (\$)
(Age POC <u>I. T</u> <u>J. F</u> <u>K. 1</u>	unizant Federal Agency incy Name, POC Name, and Phone Number) otal Direct and Indire Fee Total Costs and Fee			Tect Instituti	otal Inc	lirect Costs	Funds Requested (\$)
(Age POC <u>J. F</u> <u>K. 1</u>	unizant Federal Agency mcy Name, POC Name, and Phone Number) otal Direct and Indire ēee			Tect Instituti	otal Inc	bsts (G + H)	Funds Requested (\$) Funds Requested (\$) Funds Requested (\$) Funds Requested (\$)



U.S. Department of Health & Human Services



NIH Director's New Innovator Award (DP2)

Gene Carstea, PhD


Scientific Review Officer, New Innovator Award Review Chief, Cardiovascular and Respiratory Sciences (CVRS) IRG CSR, NIH

> 2022-23 Webinar June 23, 2022





New Innovator Award Review Process








Peer-Review Process – Pre-Stage 1

- > Applications will be assigned to one of 2 equivalent panels ...
 - both panels will reside within:
 - Respiratory, Cardiac and Circulatory Sciences (RCCS) Review Branch
- > Administrative Review: A check for completeness and ESI eligibility
- > Applications are grouped based on areas of science, as identified by applicant
- Potential Conflicts of Interest will be considered for each application
 o e.g., Institutional, Collaborative, etc.
- > Mail Reviewers will be recruited to cover all representative areas of science





Peer-Review Process: Stage 1 (Mail Reviews)



- 1. "Importance and Potential Impact of the Scientific Problem"
- 2. "Novelty / Innovativeness of Approach"
- 3. "Creative Potential of ESI"

Overall Impact Paragraph





Selection of *Finalist* Applications for Stage 2

- ✓ Selection based on Rank Score order by Mail reviewers
 - Overall Impact Scores
- \checkmark Unbiased selection of applications by Editorial reviewers
 - Combination of Scores and Impact statements

In total: Approx. 20% of all submitted applications will advance to Stage 2







Stage 2: Editorial Review

- "Editorial board" will consist of ~15-20 panelists
 - \circ senior members of the scientific community
 - $\circ~$ experts with broad scientific understanding
- Each finalist application is assigned to 3 Editor/Reviewers
 - \circ $\,$ all finalist applications will be discussed
- Scoring is focused on Impact & Innovation
- Release of *Final Scores* and *Summary Statements* (for all)
 - For Discussed applications: Summary Statements will include a Final Score along with a resume / summary of discussion
 - Non-Discussed statements: will receive 1st stage critiques





Questions about the Review process?

Contact:

Gene Carstea SRO, New Innovator Award Chief, RCCS Review Branch <u>NewInnovator_Review@mail.nih.gov</u>





Please submit your questions in the "Q&A" box (scientific inquiries will not be discussed)


Eligibility





Office of Strategic Coordination - The Common Fund

NIH DIRECTOR'S NEW INNOVATOR AWARD






June 23, 2022 @ 3:00 PM EDT

Please submit your questions in the "Q&A" box (scientific inquiries will not be discussed)

Application & Submission



National Institutes of Health Office of Strategic Coordination - The Common Fund NIH DIRECTOR'S NEW INNOVATOR AWARD






Please submit your questions in the "Q&A" box (scientific inquiries will not be discussed)

Budget



National Institutes of Health Office of Strategic Coordination - The Common Fund NIH DIRECTOR'S NEW INNOVATOR AWARD





Please submit your questions in the "Q&A" box (scientific inquiries will not be discussed)

Review





National Institutes of Health Office of Strategic Coordination - The Common Fund NIH DIRECTOR'S NEW INNOVATOR AWARD



Q&A Webinar

June 23, 2022 @ 3:00 PM EDT

Thank you for attending.

A recording of the webinar & slides will be posted on <u>commonfund.nih.gov/newinnovator</u>.

For additional questions, email us at <u>NewInnovatorAwards@mail.nih.gov</u>.





NIH DIRECTOR'S NEW INNOVATOR AWARD

